文献速递淋巴瘤

复发时机与弥漫性大B细胞淋巴瘤不同演化动力学相关

Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2023-06-15

该研究在221例一线治疗后进展/复发的弥漫性大B细胞淋巴瘤患者中分析二线(免疫)化疗联合自体干细胞移植的结局,并对129例系列活检(73例全基因组/全外显子测序)进行分子特征分析。结果显示晚期复发(>2年)的结局优于原发难治(<9个月)或早期复发(9-24个月),晚期复发常代表遗传学上不同且未接受过化疗的疾病。

要点

  • 晚期复发(>2年)患者二线治疗及ASCT结局优于原发难治(<9个月)或早期复发(9-24个月)。
  • 诊断与复发活检在细胞起源分型及遗传学子群上多一致,但晚期复发与诊断样本共享突变少,呈分支演化。
  • 高度 divergent 肿瘤中同一批基因独立获得新突变,提示共享前体细胞最早突变约束演化方向。

核心结论

  • 晚期复发通常代表遗传学上不同且未接受过化疗的疾病,对最佳患者管理有启示。

研究设计与样本

  • 基于人群的队列研究,221例一线治疗后进展/复发的DLBCL患者接受二线(免疫)化疗并意向性行ASCT。
  • 部分重叠的129例系列DLBCL活检行分子特征分析,其中73例行全基因组或全外显子测序。

主要发现

  • 晚期复发(>2年)患者二线治疗及ASCT结局优于原发难治(<9个月)或早期复发(9-24个月)患者。
  • 诊断与复发活检在细胞起源分型及遗传学子群上大多一致。
  • 仅见于各活检的突变数量随诊断后时间延长而增加,晚期复发与诊断样本共享突变少,呈分支演化模式。
  • 在高度 divergent 的肿瘤中,许多相同基因在各肿瘤中独立获得新突变,提示共享前体细胞的最早突变约束肿瘤向相同遗传学子群演化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is cured in more than 60% of patients, but outcomes remain poor for patients experiencing disease progression or relapse (refractory or relapsed DLBCL [rrDLBCL]), particularly if these events occur early. Although previous studies examining cohorts of rrDLBCL have identified features that are enriched at relapse, few have directly compared serial biopsies to uncover biological and evolutionary dynamics driving rrDLBCL. Here, we sought to confirm the relationship between relapse timing and outcomes after second-line (immuno)chemotherapy and determine the evolutionary dynamics that underpin that relationship. PATIENTS AND METHODS: Outcomes were examined in a population-based cohort of 221 patients with DLBCL who experienced progression/relapse after frontline treatment and were treated with second-line (immuno)chemotherapy with an intention-to-treat with autologous stem-cell transplantation (ASCT). Serial DLBCL biopsies from a partially overlapping cohort of 129 patients underwent molecular characterization, including whole-genome or whole-exome sequencing in 73 patients. RESULTS: Outcomes to second-line therapy and ASCT are superior for late relapse (>2 years postdiagnosis) versus primary refractory (<9 months) or early relapse (9-24 months). Diagnostic and relapse biopsies were mostly concordant for cell-of-origin classification and genetics-based subgroup. Despite this concordance, the number of mutations exclusive to each biopsy increased with time since diagnosis, and late relapses shared few mutations with their diagnostic counterpart, demonstrating a branching evolution pattern. In patients with highly divergent tumors, many of the same genes acquired new mutations independently in each tumor, suggesting that the earliest mutations in a shared precursor cell constrain tumor evolution toward the same genetics-based subgroups at both diagnosis and relapse. CONCLUSION: These results suggest that late relapses commonly represent genetically distinct and chemotherapy-naïve disease and have implications for optimal patient management.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hilton LK, Ngu HS, Collinge B, et al. Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2023. PMID: 37319384. doi:10.1200/JCO.23.00570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。